Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 7/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.44 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30121977 | 0.90 | MDM2 (0.64) | MDM2TP53ALDH1A1GAAHTT | |
| SCHEMBL17366156 | 0.89 | MDM2 (0.60) | MDM2TP53ALDH1A1GAAHTT | |
| SCHEMBL17366151 | 0.84 | MDM2 (0.58) | MDM2TP53ALDH1A1GAAHTT | |
| SCHEMBL17366174 | 0.84 | MDM2 (0.58) | MDM2TP53ALDH1A1GAAHTT | |
| SCHEMBL17366169 | 0.84 | MDM2 (0.58) | MDM2TP53ALDH1A1GAAHTT | |
| SCHEMBL17366179 | 0.81 | MDM2 (0.55) | MDM2TP53ALDH1A1MAPTMEN1 | |
| SCHEMBL17366150 | 0.81 | MDM2 (0.55) | MDM2TP53ALDH1A1GAAHTT | |
| SCHEMBL8274847 | 0.80 | MEN1 (0.55) | MDM2ALDH1A1GAAHTTNPSR1 | |
| SCHEMBL17366148 | 0.80 | CYP2C9 (0.57) | MDM2TP53MEN1KMT2A | |
| SCHEMBL8272076 | 0.79 | TP53 (0.59) | MDM2TP53ALDH1A1GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2960233-B1 | NEW THERAPEUTIC AGENTS | CANCER RESEARCH TECH LTD (GB) | 2019-10-30 | — | — | EP | disclosed |
| US-10414726-B2 | Therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-09-17 | — | — | US | disclosed |
| US-20180118684-A1 | THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| EP-2960233-A1 | NEW THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2015-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118684-A1 | THERAPEUTIC AGENTS | TP53, MDM2, TP53BP1 | MDM2 2/4885TP53 1/4885ALDH1A1 2445/4885 |
| US-10414726-B2 | Therapeutic agents | TP53, MDM2, TP53BP1 | MDM2 2/4885TP53 1/4885ALDH1A1 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.